Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to enhance the utility of the Orange Book to foster drug competition

January 30, 2019 – One of our key policy priorities is encouraging the timely development and approval of generics and biosimilars. Our efforts have helped foster competition in the marketplace with the ultimate goal of improving access to high quality, affordable treatment options for Americans and improving patient care. We’ve made significant progress over the past year advancing efforts that have helped to strengthen and streamline the generic drug review … (leggi tutto)